Daily roundupTuesday's key coronavirus developments from Luxembourg and abroad

Starting with Luxembourg

• The latest figures from the Ministry of Health show that 53 new cases of coronavirus were discovered over the last 24 hours.

• While they have not yet reached an official decision, Luxembourg’s health authorities do not exclude the possibility of recommending a third vaccine dose.

• Despite the lockdown, the emergency service‘s activity remained overall similar to previous years.

• The rapid tests from the Chinese manufacturer LEPU will continue to be distributed in Luxembourg’s schools, despite recalls in the US.

• According to the most recent analysis by the National Council of Public Finance (CNFP), the country’s economic potential turns out to be more robust than previously anticipated.

• It’s the time of year again where passports get stamped, tan lines make their comeback and the world seems to take the foot off the gas pedal to sit back and relax. But how to pack your bags effectively for the holiday season? Our Do’s and Don’ts.

And abroad

• [block type="summary”]More than three billion doses of Covid-19 vaccines have been given across the world. The pace of vaccination has so quickened that while it took 20 weeks to give the first billion, it only took four to give the last one thousand million.

  • India authorised the emergency use of Moderna’s Covid-19 vaccine on Tuesday as it seeks to ramp up inoculations in the wake of a record-breaking surge in infections and deaths.
  • Young people in Greece will be eligible for a prepaid card worth 150 euros, upon receiving their first Covid-19 vaccine dose.
  • Covid-19 infections are rising again in Europe after falling for two and a half months, mainly because of the Delta variant in the UK and Russia. This week’s cases were 21% higher compared to last week.
  • French pharmaceutical giant Sanofi said Tuesday that it would invest 2 billion euros in the mRNA vaccine technology behind the pioneering Covid-19 jabs developed by rivals BioNTech-Pfizer and Moderna. It said it would set up an mRNA “centre of excellence” employing 400 people at its laboratories in the US city of Cambridge and Marcy-L’Etoile near the French city of Lyon.
  • Tiny sensors incorporated into wearable fabrics like masks and jackets could provide instant information on exposure to disease-causing pathogens such as the coronavirus, according to research published on Monday in the journal Nature Biotechnology.